LALINDEN ADVISORS LP

Institutional investor · Portfolio as of Q3 2024

Top Holdings277 positions

Checking export access…
Activity:
??MICROSTRATEGY INCDelisted
Bond
233.4M$318.6M2.7%———
Increased
74
??INSMED INCDelisted
Bond
133.7M$307.2M2.6%——
2 qtrssince 2024-Q2
Increased
60
??CONFLUENT INCDelisted
Bond
322.6M$286.6M2.4%———
Increased
53
??LI AUTO INCDelisted
Bond
220.8M$263.5M2.2%——
10 qtrssince 2022-Q2
Increased
73
95M$253.6M2.1%———
Increased
67
132.2M$244.1M2.1%———
Increased
57
277.3M$241.2M2.0%———
Decreased
0
??MONGODB INCDelisted
Bond
165M$227.8M1.9%———
Decreased
0
??SEA LTD
Bond
247.7M$224.2M1.9%———
Increased
63
207.9M$222.3M1.9%———
Increased
54
168.7M$218.8M1.8%———
Increased
58
??SNAP INC
Bond
260.6M$208.6M1.8%———
Decreased
0
??ASCENDIS PHARMA A/SDelisted
Bond
175.2M$204.7M1.7%———
Increased
59
84.3M$204.6M1.7%———
Increased
57
??LIVONGO HEALTH INCDelisted
Bond
186.5M$180.8M1.5%———
Increased
48
75M$150M1.3%———
Decreased
0
144.9M$149.9M1.3%———
Increased
77
172.5M$149.5M1.3%——
7 qtrssince 2023-Q1
Increased
50
159.3M$147.2M1.2%———
Increased
48
137.3M$145.1M1.2%———
New
69
$11.9B
AUM
277
Positions
Q3 2024
Filing
HI score · 2.5/5
Quarterly 13F Value Change
-13%Q4'22$9.5B-0%Q1'23$9.5B+0%Q2'23$9.5B+2%Q3'23$9.7B+8%Q4'23$10.5B+14%Q2'24$12B
Activity profile
$ moved · Q3'24
New17%Increased31%Decreased22%Exited30%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 1.7 years
<1Q13%1-4Q19%1-2Y25%2Y+44%

LINDEN ADVISORS LP manages $11.9B across 277 positions as of Q3 2024. Top holdings: MICROSTRATEGY INC (2.7%), INSMED INC (2.6%), CONFLUENT INC (2.4%). Fund DNA: Diversified Scout. HoldingsIntel Score: 2.5/5.0.

Q3 2024 Summary

Active quarter - 38 new positions, 52 exits, 67 increased. No standout high-conviction moves this quarter. Portfolio: $11.9B across 277 positions.

Top holdings by portfolio weight

Total AUM$12B
MICROSTRATEG2.68%
INSMED INC2.59%
CONFLUENT IN2.41%
LI AUTO INC2.22%
UNITED STATE2.13%
TRANSMEDICS 2.05%
DRAFTKINGS I2.03%
MONGODB INC1.92%
SEA LTD1.89%
ZTO EXPRESS 1.87%
Other1.84%

Portfolio allocation by GICS sector

Sectors6
Unknown62.76%
Financial Services16.69%
Technology13.70%
Basic Materials6.17%
Utilities0.47%
Industrials0.21%

Behavioral investing profile

Checking access…
Diversified Scout
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Solid(2.5 / 5.0)
Holdings P&L57
Conviction31
Concentration37
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
7Q
BR10806XAD4BRIDGEBIO PHARMA INC
Q4 2024 → Q2 2026+151.4M shares+$192.5M
7Q
VI928298AR9VISHAY INTERTECHNOLOGY INC.
Q4 2024 → Q2 2026+353.9M shares+$770.5M
4Q
CO19459JAC8COLLEGIUM PHARMACEUTICAL INC
Q3 2025 → Q2 2026+26.6M shares+$50.6M
Checking access…

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used